PTK2 and neoplasm: In NSCLC cells resistant to the TKI dasatinib, the addition of FAK inhibitor PF-271 to dasatinib treatment inhibited tumor growth to a greater extent than either treatment alone, indicating the contribution of FAK to dasatinib resistance in NSCLC [44].